Rhythm Pharmaceuticals In... (RYTM)
57.81
-0.19 (-0.33%)
At close: Feb 20, 2025, 3:59 PM
57.74
-0.12%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 55.59 |
| Market Cap | 3.55B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -4.32 |
| PE Ratio (ttm) | -13.38 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 59.87 |
| Volume | 205,766 |
| Avg. Volume (20D) | 494,720 |
| Open | 57.81 |
| Previous Close | 58.00 |
| Day's Range | 56.69 - 58.38 |
| 52-Week Range | 35.17 - 68.58 |
| Beta | undefined |
About RYTM
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström sy...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 9, 2017
Employees 226
Stock Exchange NASDAQ
Ticker Symbol RYTM
Website https://www.rhythmtx.com
Analyst Forecast
According to 10 analyst ratings, the average rating for RYTM stock is "Buy." The 12-month stock price forecast is $67.5, which is an increase of 16.76% from the latest price.
Buy 90.00%
Hold 10.00%
Sell 0.00%
Next Earnings Release
Rhythm Pharmaceuticals Inc. is scheduled to release its earnings on Feb 26, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+11.38%
Rhythm Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
5 months ago
+7.37%
Rhythm Pharmaceuticals shares are trading higher after JMP Securities initiated coverage on the stock with a Market Outperform rating and announced a price target of $64.
